日本の心臓バイオマーカー市場レポート：タイプ別、検査場所別、用途別、地域別、2025～2033年

日本の心臓バイオマーカー市場規模は2024年に6億8,010万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに13億270万米ドルに達し、2025～2033年にかけて7.5%の成長率（CAGR）を示すと予測しています。心臓発作、脳卒中、心不全など、患者の早期発見、リスク評価、モニタリングを必要とする心血管疾患の有病率の増加が市場を牽引しています。

本レポートで扱う主要質問

• 日本の心臓バイオマーカー市場はこれまでどのように推移し、今後どのように推移していくのか？
• COVID-19が日本の心臓バイオマーカー市場に与えた影響は？
• 日本の心臓バイオマーカー市場のタイプ別区分は？
• 日本の心臓バイオマーカー市場の検査部位による区分は？
• 国内の心臓バイオマーカー市場の用途別区分は？
• 日本の心臓バイオマーカー市場のバリューチェーンにおける様々なステージとは？
• 日本の心臓バイオマーカーの主要な促進要因と課題は？
• 日本の心臓バイオマーカー市場の構造と主要参入企業は？
• 日本の心臓バイオマーカー市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本の心臓バイオマーカー市場-イントロダクション

• 概要
• 市場力学
• 産業動向
• 競合情報

第5章 日本の心臓バイオマーカー市場情勢

• 過去と現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本の心臓バイオマーカー市場-タイプ別内訳

• トロポニン（TとI）
• 心筋クレアチンキナーゼ（CK-MB）
• ミオグロビン
• 脳性ナトリウム利尿ペプチド（BNP）またはNT-proBNP
• 虚血修飾アルブミン（IMA）
• その他

第7章 日本の心臓バイオマーカー市場-検査場所別内訳

• 臨床検査
• ポイントオブケア検査

第8章 日本の心臓バイオマーカー市場-用途別内訳

• 心筋梗塞
• うっ血性心不全
• 急性冠症候群
• 動脈硬化症
• その他

第9章 日本の心臓バイオマーカー市場-競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第10章 主要企業のプロファイル

第11章 日本の心臓バイオマーカー市場-産業分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第12章 付録

Japan cardiac biomarkers market size reached USD 680.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,302.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.5% during 2025-2033. The increasing prevalence of cardiovascular diseases such as heart attacks, strokes, and heart failure, that require cardiac biomarkers for early detection, risk assessment, and monitoring of patients, is driving the market.

Cardiac biomarkers are proteins or molecules released into the bloodstream in response to heart-related conditions. They play a crucial role in diagnosing and monitoring various heart disorders. Common cardiac biomarkers include troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP). Troponins are highly specific indicators of heart muscle damage and are essential in diagnosing heart attacks. CK-MB is another enzyme that rises in response to heart muscle injury. BNP, on the other hand, helps assess heart failure and its severity. Measuring cardiac biomarkers through blood tests allows healthcare professionals to detect and evaluate heart problems, determine the extent of damage, and formulate appropriate treatment plans. These biomarkers provide valuable insights into the overall health of the heart and help guide medical interventions to improve patient outcomes. Regular monitoring of cardiac biomarkers is essential in managing heart conditions and preventing complications.

Japan Cardiac Biomarkers Market Trends:

The cardiac biomarkers market in Japan is poised for substantial growth, driven by several key factors. Firstly, the escalating prevalence of cardiovascular diseases, including coronary artery disease and heart failure, has significantly increased the demand for cardiac biomarker testing. Additionally, the aging regional population is a major driver, as older individuals are at higher risk of cardiac-related issues, creating a sustained need for cardiac biomarker diagnostics. Moreover, advancements in medical technology and the increasing adoption of high-sensitivity cardiac biomarker assays have enhanced the accuracy and efficiency of cardiac disease detection. This has not only improved patient outcomes but also encouraged healthcare providers to incorporate these tests into their routine clinical practices. Furthermore, the growing awareness among both healthcare professionals and patients regarding the importance of early cardiac disease detection and prevention has led to increased testing rates. The emphasis on preventive healthcare and proactive monitoring of cardiac health has bolstered the cardiac biomarkers market. Lastly, supportive government initiatives and funding for cardiovascular research and diagnostic tools have fueled market expansion. Overall, these drivers converge to create a favorable landscape for the cardiac biomarkers market's sustained growth in the foreseeable future.

Japan Cardiac Biomarkers Market Segmentation:

Type Insights:

• Troponins (T and I)
• Myocardial Muscle Creatine Kinase (CK-MB)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

Location of Testing Insights:

• Laboratory Testing
• Point of Care Testing

Application Insights:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan cardiac biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan cardiac biomarkers market?
• What is the breakup of the Japan cardiac biomarkers market on the basis of type?
• What is the breakup of the Japan cardiac biomarkers market on the basis of location of testing?
• What is the breakup of the Japan cardiac biomarkers market on the basis of application?
• What are the various stages in the value chain of the Japan cardiac biomarkers market?
• What are the key driving factors and challenges in the Japan cardiac biomarkers?
• What is the structure of the Japan cardiac biomarkers market and who are the key players?
• What is the degree of competition in the Japan cardiac biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cardiac Biomarkers Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Cardiac Biomarkers Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Cardiac Biomarkers Market - Breakup by Type

• 6.1 Troponins (T and I)
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Myoglobin
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Ischemia Modified Albumin (IMA)
  • 6.5.1 Overview
  • 6.5.2 Historical and Current Market Trends (2019-2024)
  • 6.5.3 Market Forecast (2025-2033)
• 6.6 Others
  • 6.6.1 Historical and Current Market Trends (2019-2024)
  • 6.6.2 Market Forecast (2025-2033)

7 Japan Cardiac Biomarkers Market - Breakup by Location of Testing

• 7.1 Laboratory Testing
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Point of Care Testing
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)

8 Japan Cardiac Biomarkers Market - Breakup by Application

• 8.1 Myocardial Infarction
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Congestive Heart Failure
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)
• 8.3 Acute Coronary Syndrome
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2019-2024)
  • 8.3.3 Market Forecast (2025-2033)
• 8.4 Atherosclerosis
  • 8.4.1 Overview
  • 8.4.2 Historical and Current Market Trends (2019-2024)
  • 8.4.3 Market Forecast (2025-2033)
• 8.5 Others
  • 8.5.1 Historical and Current Market Trends (2019-2024)
  • 8.5.2 Market Forecast (2025-2033)

9 Japan Cardiac Biomarkers Market - Competitive Landscape

• 9.1 Overview
• 9.2 Market Structure
• 9.3 Market Player Positioning
• 9.4 Top Winning Strategies
• 9.5 Competitive Dashboard
• 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

• 10.1 Company A
  • 10.1.1 Business Overview
  • 10.1.2 Services Offered
  • 10.1.3 Business Strategies
  • 10.1.4 SWOT Analysis
  • 10.1.5 Major News and Events
• 10.2 Company B
  • 10.2.1 Business Overview
  • 10.2.2 Services Offered
  • 10.2.3 Business Strategies
  • 10.2.4 SWOT Analysis
  • 10.2.5 Major News and Events
• 10.3 Company C
  • 10.3.1 Business Overview
  • 10.3.2 Services Offered
  • 10.3.3 Business Strategies
  • 10.3.4 SWOT Analysis
  • 10.3.5 Major News and Events
• 10.4 Company D
  • 10.4.1 Business Overview
  • 10.4.2 Services Offered
  • 10.4.3 Business Strategies
  • 10.4.4 SWOT Analysis
  • 10.4.5 Major News and Events
• 10.5 Company E
  • 10.5.1 Business Overview
  • 10.5.2 Services Offered
  • 10.5.3 Business Strategies
  • 10.5.4 SWOT Analysis
  • 10.5.5 Major News and Events

11 Japan Cardiac Biomarkers Market - Industry Analysis

• 11.1 Drivers, Restraints, and Opportunities
  • 11.1.1 Overview
  • 11.1.2 Drivers
  • 11.1.3 Restraints
  • 11.1.4 Opportunities
• 11.2 Porters Five Forces Analysis
  • 11.2.1 Overview
  • 11.2.2 Bargaining Power of Buyers
  • 11.2.3 Bargaining Power of Suppliers
  • 11.2.4 Degree of Competition
  • 11.2.5 Threat of New Entrants
  • 11.2.6 Threat of Substitutes
• 11.3 Value Chain Analysis

12 Appendix